These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9777181)

  • 1. Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period.
    Sharma RP; Javaid JI; Davis JM; Janicak PG
    Biol Psychiatry; 1998 Sep; 44(6):488-92. PubMed ID: 9777181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma HVA in psychiatric patients: longitudinal studies.
    Javaid JI; Sharma RP; Janicak PG; Davis JM
    Psychopharmacol Bull; 1990; 26(3):361-5. PubMed ID: 2274637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.
    Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
    Biol Psychiatry; 1997 Mar; 41(5):560-6. PubMed ID: 9046988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
    Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
    Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haloperidol response and plasma catecholamines and their metabolites.
    Green AI; Alam MY; Boshes RA; Waternaux C; Pappalardo KM; Fitzgibbon ME; Tsuang MT; Schildkraut JJ
    Schizophr Res; 1993 Jun; 10(1):33-7. PubMed ID: 8369230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia.
    Muscettola G; Barbato G; de Bartolomeis A; Monteleone P; Pickar D
    Psychiatry Res; 1990 Sep; 33(3):259-67. PubMed ID: 2243901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response.
    Koreen AR; Lieberman J; Alvir J; Mayerhoff D; Loebel A; Chakos M; Amin F; Cooper T
    Arch Gen Psychiatry; 1994 Feb; 51(2):132-8. PubMed ID: 7905259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between plasma homovanillic acid levels and the response to atypical antipsychotics in male patients with schizophrenia.
    Kaneda Y; Kawamura I; Ohmori T
    Clin Neuropharmacol; 2005; 28(6):262-4. PubMed ID: 16340379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine.
    Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
    Psychiatry Res; 1997 Mar; 69(2-3):113-21. PubMed ID: 9109179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma homovanillic acid in schizophrenics: supportive evidence for the two-subtype hypothesis.
    Chen TY; Lee CF; Lung FW; Lee TC; Lin WL; Hu WH; Yeh EK; Chang WH
    Taiwan Yi Xue Hui Za Zhi; 1989 Jun; 88(6):584-8. PubMed ID: 2571672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma homovanillic acid and treatment response in a large group of schizophrenic patients.
    Chang WH; Hwu HG; Chen TY; Lin SK; Lung FW; Chen H; Lin WL; Hu WH; Lin HN; Chien CP
    Schizophr Res; 1993 Oct; 10(3):259-65. PubMed ID: 8260444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
    Khan RS; Amin F; Powchik P; Knott P; Goldstein M; Apter S; Kerman B; Jaff S; Davidson M
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):879-84. PubMed ID: 1980541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis.
    Mazure CM; Nelson JC; Jatlow PI; Bowers MB
    Biol Psychiatry; 1991 Sep; 30(5):475-82. PubMed ID: 1932395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia.
    Zhang ZJ; Reynolds GP; Ramchand C; Peet M; Shah S
    Acta Pharmacol Sin; 2001 Jan; 22(1):76-80. PubMed ID: 11730567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
    Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between plasma homovanillic acid and outcome in patients with psychosis spectrum disorders.
    van de Kerkhof NW; Fekkes D; van der Heijden FM; Egger JI; Verhoeven WM
    Neuropsychobiology; 2015; 71(4):212-7. PubMed ID: 26279280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of plasma homovanillic acid (HVA) in chronic schizophrenic patients treated with haloperidol.
    Galinowski A; Poirier MF; Aymard N; Leyris A; Beauverie P; Bourdel MC; Loo H
    Acta Psychiatr Scand; 1998 Jun; 97(6):458-66. PubMed ID: 9669519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of plasma homovanillic acid (HVA) levels during treatment in schizo-affective disorder.
    Galinowski A; Castelnau C; Spreux-Varoquaux O; Bourdel MC; Olie JP; Loo H; Poirier MF
    Prog Neuropsychopharmacol Biol Psychiatry; 2000 Nov; 24(8):1319-28. PubMed ID: 11125856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A biomodal distribution of plasma HVA/MHPG in the psychoses.
    Ottong SE; Garver DL
    Psychiatry Res; 1997 Mar; 69(2-3):97-103. PubMed ID: 9109177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
    Dávila R; Zumárraga M; Basterreche N; Arrúe A; Anguiano JB
    Psychiatry Res; 2007 May; 151(1-2):163-8. PubMed ID: 17434602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.